Average Co-Inventor Count = 6.26
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Regeneron Pharmaceuticals, Inc. (26 from 1,342 patents)
2. Regeneran Pharmaceuticals, Inc. (3 from 49 patents)
29 patents:
1. 12344677 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
2. 12258412 - Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies
3. 12150959 - Chimeric antigen receptors with BCMA specificity and uses thereof
4. 12115216 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
5. 12091460 - Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
6. 11905332 - Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
7. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
8. 11608380 - Anti-EGFRvIII antibodies and uses thereof
9. 11559576 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
10. 11485793 - Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
11. 11434300 - Methods and antibody compositions for tumor treatment
12. 11384153 - Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof
13. 11155633 - Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
14. 10941208 - Anti-MUC16 antibodies
15. 10925971 - Methods of treating PRLR positive breast cancer